Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2020-09-11 Report Publication Anno…
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Zmiana terminu publikacji raportu okresowego za I półrocze 2020 roku - Content (PL)
Report Publication Announcement Classification · 1% confidence The document text is very short (343 characters) and explicitly states that the company is informing the public about a *change in the date* for releasing its periodic report for the first half of 2020. It announces *when* the report will be published (September 25, 2020), rather than containing the report itself. This fits the definition of announcing the publication or timing of a report. Therefore, the most appropriate classification is Report Publication Announcement (RPA).
2020-09-11 Polish
Zarekomendowanie przez NCBR do dofinansowania projektu Spółki - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a short announcement from the Management Board (Zarząd) of Celon Pharma S.A. regarding the recommendation for funding (dofinansowanie) of a project related to an antiviral therapeutic for COVID-19 by the National Centre for Research and Development (NCBR). This concerns fundraising, financing activities, or capital structure changes related to a specific project. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a full report, earnings release, or management discussion, but a specific announcement about securing funding/grants.
2020-09-09 Polish
Pozytywne zakończenie pierwszej części badania I fazy klinicznej agonisty receptora GPR40 - CLP207280, w leczeniu cukrzycy typu II oraz neuropatii cukrzycowych. - Content (PL)
Regulatory Filings Classification · 1% confidence The document text discusses an update regarding a clinical trial (Phase I study completion for a drug candidate, CLP207280) related to diabetes treatment. It reports on the drug's tolerability and lack of hepatotoxicity observed so far. This type of specific, ongoing operational/development update, especially concerning clinical progress, does not fit neatly into standard financial reports (10-K, IR, ER) or corporate governance documents. It is an announcement about a specific operational milestone in drug development. Given the available categories, this is best classified as a general Regulatory Filing (RNS) as it is a specific, non-standard operational update that is likely required for regulatory disclosure but doesn't match the other specific categories like M&A (TAR), Financing (CAP), or Director Dealing (DIRS). The document length is short, but it contains substantive information rather than just announcing another report.
2020-07-23 Polish
Złożenie wniosku o zgodę na rozpoczęcie badania klinicznego II fazy nad lekiem opartym o innowacyjny inhibitor PDE10A rozwijany w leczeniu zaburzeń psychotycznych i neuromotorycznych - CPL500036 - ...
Regulatory Filings Classification · 1% confidence The document is a formal announcement from Celon Pharma S.A. regarding an update on a clinical trial for a drug candidate (CPL500036). It details the submission of an application to the regulatory body (Urząd Rejestracji Produktów Leczniczych Wyrobów Medycznych i Produktów Biobójczych) to start Phase II clinical trials for schizophrenia. This content relates to ongoing research, development, and regulatory steps concerning a product, which falls under the scope of general regulatory announcements or potentially legal/regulatory updates, but most closely aligns with a general regulatory filing that isn't a standard financial report (10-K, IR, ER). Given the options, this is a specific regulatory update concerning product development and regulatory submission. It is not a standard financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a director's dealing (DIRS). Since it is a formal notification to the market about a regulatory step (filing for Phase II trial approval), it best fits the general 'Regulatory Filings' category (RNS) as a miscellaneous, non-standard announcement, or potentially 'LTR' if viewed as a regulatory action update, but RNS is the broader fallback for such specific, non-financial regulatory news. Considering the nature of the announcement (update on clinical trial progress and regulatory submission), RNS (Regulatory Filings) is the most appropriate general classification for this type of corporate event disclosure that doesn't fit a more specific financial or governance category.
2020-06-09 Polish
Wykaz akcjonariuszy posiadających co najmniej 5% głosów na Zwyczajnym Walnym Zgromadzeniu Spółki w dniu 19 maja 2020 r. - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document text is very short (727 characters) and explicitly mentions the 'Zwyczajnym Walnym Zgromadzeniu Spółki' (Annual General Meeting) held on May 19, 2020. It then lists the shareholders who held at least 5% of the votes at that meeting, detailing their share counts and voting percentages. This content directly relates to the results or official proceedings of a shareholder vote at a general meeting. Therefore, the most appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2020-05-22 Polish
Załącznik do uchwały nr 22 ZWZ Celon Pharma SA 19-05-2020
Remuneration Information Classification · 1% confidence The document is titled "POLITYKA WYNAGRODZEŃ CZŁONKÓW ZARZĄDU I RADY NADZORCZEJ" (Remuneration Policy for Management Board and Supervisory Board Members). It explicitly details the principles, structure, and criteria for compensating board members and management. This directly aligns with the definition of Remuneration Information (DEF 14A), which covers compensation for top executives and directors. Although the document is a policy rather than a specific annual report on past compensation (which is referred to as 'Sprawozdanie o wynagrodzeniach' within the text), the core subject matter is executive remuneration disclosure, making DEF 14A the most appropriate classification among the provided options, as it covers the regulatory disclosure around compensation.
2020-05-20 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.